In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 261 to 270 of 294

TitleTypeExpected publication date
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]Technology appraisal guidanceTBC
Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]Technology appraisal guidanceTBC
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]Technology appraisal guidanceTBC
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]Technology appraisal guidance
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]Technology appraisal guidance
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis [ID6351]Technology appraisal guidanceTBC
Tolebrutinib for treating primary progressive multiple sclerosis [ID6574]Technology appraisal guidance
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]Technology appraisal guidanceTBC
Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713Technology appraisal guidanceTBC
Topical tapinarof for treating mild to severe plaque psoriasis ID6712Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All